Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
IPO Year:
Exchange: NASDAQ
Website: silence-therapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2024 | $40.00 | Buy | Jefferies |
| 1/31/2024 | $67.00 | Outperform | BMO Capital Markets |
| 5/8/2023 | $20.00 | Overweight | Morgan Stanley |
| 12/9/2022 | $18.00 | Equal-Weight | Morgan Stanley |
| 3/31/2022 | $33.00 | Buy | Chardan Capital Markets |
New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose Represents first study to report time-averaged Lp(a) results to further evaluate potential clinical benefits Data simultaneously published in the Journal of the American Medical Association Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disea
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights. "The Silence team is focused on continued execution across the business," said Craig Tooman, President and Chief Executive Officer at Silence. "We look forward to presenting additional data from our wholly owned clinical programs at upcoming medical meetings and progressing our pipeline to bring innovative gene silencing medicines to patients around the
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20th at 2:00 p.m. GMT. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people'
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that management will present company overviews at the following conferences: Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024 at 5:35pm ET HC Wainwright Global Investment Conference on Tuesday, September 10, 2024 at 11:30am ET Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 10:20am ET Chardan Genetic Medicines Conference on Monday, September 30, 2024 at 9:00am ET A live audio webcast of each pr
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its financial results for the second quarter ended June 30, 2024 and reviewed recent business highlights. "The first half of this year has been marked by strong execution across Silence, including outstanding clinical results in both our wholly owned clinical programs and advancing our first partnered program into the clinic under our AstraZeneca collaboration," said Craig Tooman, President and Chief Executive Officer at Silence. "Silence's siRNA technolo
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision engineered medicines, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited ("Hansoh") following the achievement of a second undisclosed milestone related to the first target under the collaboration. "This represents an important milestone in our efforts to advance this program into the clinic with Hansoh," said Craig Tooman, President and CEO of Silence. "This is an exciting time for Silence and our mRNAi GOLD™ platform as we conti
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive topline 48-week data from the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events. Zerlasiran is a siRNA (short interfering RNA) designed to lower t
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will present at the Jefferies Global Healthcare Conference on Thursday, June 6th at 2:30 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interferenc
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights. "Silence's first quarter performance reflects another period of solid execution with the continued advancement of both our wholly owned and partnered pipelines in the clinic," said Craig Tooman, President and Chief Executive Officer at Silence. "Silence is well positioned heading into key data readouts in our zerlasiran and divesiran programs, and we
6-K - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
F-3ASR - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
EFFECT - Silence Therapeutics plc (0001479615) (Filer)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13D/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G - Silence Therapeutics plc (0001479615) (Subject)
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $45 to $49.
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and raises the price target from $42 to $55.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
Of the 16 patients, 8 patients are considered well-controlled and 8 patients have HCT levels over 45% at baseline. To date, divesiran has been observed to be well tolerated with no major safety issues.
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision engineered medicines, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited ("Hansoh") following the achievement of a second undisclosed milestone related to the first target under the collaboration
Analysts' ratings for Silence Therapeutics (NASDAQ:SLN) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $64.5, with a high estimate of $75.00 and a low estimate of $42.00. Holding firm without variation, the current aver
HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da
Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a) Company to host conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights. "2023 was a year of strong execution across Silence as we advanced our proprietary pipeline in the clinic," said Craig Tooman, President and
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024. Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. T
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2022, on Wednesday, March 15, 2023. Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. Th
– Positive SLN360 data to be presented in late breaker at the American College of Cardiology (ACC) Annual Meeting on April 3, 2022 – SLN124 phase 1 study in thalassemia now fully enrolled; on-track for topline data in Q3 2022 – SLN124 granted FDA orphan drug designation in polycythemia vera; on-track to start phase 1 study in H2 2022 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and review
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 17, 2022. Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT on Thursday, March 17, to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence we
Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00
BMO Capital Markets initiated coverage of Silence Therapeutics with a rating of Outperform and set a new price target of $67.00
Morgan Stanley initiated coverage of Silence Therapeutics with a rating of Overweight and set a new price target of $20.00
Morgan Stanley initiated coverage of Silence Therapeutics with a rating of Equal-Weight and set a new price target of $18.00
Chardan Capital Markets initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $33.00
Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the Board, commented, "Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the developmen
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion's retirement by year-end. Dr. Romano has served as non-execut
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff, SVP, Technical Operations. In this role, J.P. is responsible for Manufacturing, Process and Analytical Development and Supply Chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230206005194/en/J.P. Gabriel, Chief Technical Operations Officer, Silence Therapeutics plc. (Photo:
Silence Therapeutics Reports Full-year 2020 ResultsAdvancing clinical programmes; On-track for three phase 1 data readouts in 2021 30 March 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, announced its audited full year results for the year ended 31 December 2020. Mark Rothera, President and CEO of Silence Therapeutics, commented: “2020 was a transformational year for Silence Therapeutics, driven by the remarkable resilience of our people in what was a challen